Subject: Participation in survey "Drospirenone containing pills for contraception"
Combined oral contraceptives (COCs) have been the first-line therapy for concurrent treatment of menstrual irregularity, acne, and hirsutism in women with polycystic ovarian syndrome (PCOS), thus playing an important role in the symptom management of the PCOS women. The COCs also improve dysmenorrhea and menorrhagia, treat premenstrual syndrome, prevent menstrual migraines, treat pelvic pain related to endometriosis. The COC is a combination of two types of steroids; ethinyl estradiol (EE) as the main estrogenic component and progestins essentially derivatives of 19-nortestosterone.
Drospirenone, referred to as fourth-generation progestin, presents mainly progestogenic, anti-mineralocorticoid and antiandrogenic effects.
Drospirenone only preparation is neutral concerning metabolic and hemostatic parameters. At the same time, clinical trials have demonstrated a high contraceptive efficacy and an acceptable bleeding pattern.
There is limited real-world data available on the usage of drospirenone containing pills for contraception in India.
This multicentric survey is designed to understand the usage of drospirenone containing pills for contraception in India.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})